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The function of cyclin D-CDK4/6 kinases in cancer cell metabolism and anti-tumor immune surveillance P. Sicinski Cancer, Dana-Farber Cancer Institute, Boston, MA, USA D-type cyclins (D1, D2 and D3) together with their associated cyclin-dependent kinases CDK4 and CDK6 are components of the core cell cycle machinery that drives cell proliferation. Inhibitors of CDK4 and CDK6 are currently in clinical trials for patients with several cancer types, with promising results. We demonstrated that cyclin D3-CDK6 phosphorylates and inhibits the catalytic activity of two key enzymes in the glycolytic pathway, 6-phosphofructokinase and pyruvate kinase M2. This re-directs the glycolytic intermediates into the pentose phosphate (PPP) and serine pathways. Inhibition of cyclin D3-CDK6 in tumor cells reduces PPP and serine pathway flows, thereby depleting anti-oxidants NADPH and glutathione. This, in turn, elevates the levels of reactive oxygen species and causes tumor cell apoptosis. The pro-survival function of cyclin Dassociated kinase operates in tumors expressing high levels of cyclin D3-CDK6 complexes. We propose that measuring the levels of cyclin D3-CDK6 in human cancers might help to identify tumor subsets that undergo cell death and tumor regression upon CDK4/6-inhibition. Cyclin D3-CDK6, through its ability to link cell cycle and cell metabolism represents a particularly powerful oncogene that affects cancer cells at several levels, and this property can be exploited for anti-cancer therapy. Targeting immune checkpoints such as the one mediated by programmed cell death protein 1 (PD-1) and its ligand PD-L1 have been approved for treating multiple types of human cancers with durable clinical benefit. However, many cancer patients fail to respond to anti-PD-1/PD-L1 treatment, and the underling mechanism(s) is not well understood. Recent studies revealed that response to PD-L1 blockade might correlate with PD-L1 expression levels on tumor cells. Hence, it is important to mechanistically understand the pathways controlling PD-L1 protein expression and stability, which can offer a molecular basis to improve the clinical response rate and efficacy of PD-1/PD-L1 blockade in cancer patients. We found that PD-L1 protein abundance is regulated by cyclin D-CDK4, and that inhibition of CDK4/6 in vivo elevates PD-L1 protein levels. Combining CDK4/6 inhibitor treatment with anti-PD-1 immunotherapy enhanced tumor regression and dramatically improved overall survival rates in mouse tumor models. Our study uncovered a novel molecular mechanism for regulating PD-L1 protein stability by a cell cycle kinase and revealed the potential for using combination treatment with CDK4/6 inhibitors and PD-1/PD-L1 immune checkpoint blockade to enhance therapeutic efficacy for human cancers. An approach to increase the efficacy of ICI is to combine them with chemotherapy, in order to enhance immunogenic cell death and "prime" the immune system. However, chemotherapy itself can cause damage to various cell types of the immune system, potentially diminishing the activity of the ICI combination. Using trilaciclib, a shortacting IV CDK4/6 inhibitor that preserves hematopoietic stem cells and enhances immune system function during chemotherapy, we have developed a novel approach to preserve immune system function during chemotherapy to allow optimal activity of ICI.
Methods: To evaluate the efficacy of trilaciclib added to chemotherapy/ICI combinations, tumor-bearing immunocompetent mice (MC38 or CT26) were treated with trilaciclib, chemotherapy (oxaliplatin or 5-FU), or ICIs (anti-PD-L1 or anti-PD-1) alone or in combination, and tumor size was measured for up to 100 days. To gain insight into the effect of transient exposure of trilaciclib on the tumor microenvironment, we are examining the cellular composition, proliferation status and gene expression of tumor immune infiltrates from MC38 tumor-bearing mice post-treatment.
Results: The addition of trilaciclib to chemotherapy/ICI significantly improved antitumor activity and prolonged overall survival. Potential mechanisms by which transient trilaciclib exposure enhances anti-tumor activity include: reduction of Treg populations, preservation of T lymphocyte function, and changes in gene expression leading to enhanced lymphocyte activation and a pro-inflammatory tumor microenvironment.
Conclusions: These findings suggest that transient trilaciclib-induced G1 cell-cycle arrest in tumor immune infiltrates prior to chemotherapy/ICI combination treatment creates a favorable tumor microenvironment resulting in increased antitumor activity. Based on these findings, a Phase 2 study to assess the safety and efficacy of trilaciclib or placebo with carboplatin, etoposide, and atezolizumab in first-line extensive stage SCLC patients is ongoing (NCT03041311). Legal entity responsible for the study: G1 Therapeutics Funding: G1 Therapeutics Disclosure: P.J. Roberts, A.Y. Lai, J.A. Sorrentino, R.K. Malik: All authors are employees of G1 Therapeutics.
30IN Why is PI3K so hard?
M. Scaltriti Memorial Sloan-Kettering Cancer Center, New York, NY, USA Hyperactivation of the PI3K-AKT-mTOR signaling cascade occurs in a plethora of cancer types. Both preclinical data and clinical studies suggest that this pathway is a valid pharmacological target in selected patient populations. However, intrinsic and acquired drug resistance, together with emergence of intolerable side effects, limits the use of PI3K inhibitors in the clinic. There are at least two reasons that potentially explain why PI3K is so hard to tackle pharmacologically. One is the triggering of adaptive responses following treatments with PI3K inhibitors that can circumvent the antitumor activity of these agents. Upon blockade of the PI3K-AKT axis, these compensatory pathways can still sustain cell viability and proliferation, bypassing the pharmacological pressure. Hypothesis-based combinatorial strategies may prevent these molecular feedbacks and increase the efficacy of PI3K inhibitors. Another intrinsic limitation of these drugs is their limited therapeutic window. Ways to overcome this problem are a better selection of patients who are more likely to respond to these inhibitors and a better way to deliver these compounds specifically to the tumor microenvironment. Legal entity responsible for the study: N/A 
